1
|
Mattioli IA, Castro KR, Macedo LJA, Sedenho GC, Oliveira MN, Todeschini I, Vitale PM, Ferreira SC, Manuli ER, Pereira GM, Sabino EC, Crespilho FN. Graphene-based hybrid electrical-electrochemical point-of-care device for serologic COVID-19 diagnosis. Biosens Bioelectron 2021; 199:113866. [PMID: 34915214 PMCID: PMC8648586 DOI: 10.1016/j.bios.2021.113866] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Revised: 08/27/2021] [Accepted: 12/03/2021] [Indexed: 02/08/2023]
Abstract
The outbreak of COVID-19 pandemics highlighted the need of sensitive, selective, and easy-to-handle biosensing devices. In the contemporary scenario, point-of-care devices for mass testing and infection mapping within a population have proven themselves as of primordial importance. Here, we introduce a graphene-based Electrical-Electrochemical Vertical Device (EEVD) point-of-care biosensor, strategically engineered for serologic COVID-19 diagnosis. EEVD uses serologic IgG quantifications on SARS-CoV-2 Receptor Binding Domain (RBD) bioconjugate immobilized onto device surface. EEVD combines graphene basal plane with high charge carrier mobility, high conductivity, low intrinsic resistance, and interfacial sensitivity to capacitance alterations. EEVD application was carried out in real human serum samples. Since EEVD is a miniaturized device, it requires just 40 μL of sample for a point-of-care COVID-19 infections detection. When compared to serologic assays such ELISA and other immunochromatographic methods, EEVD presents some advantages such as time of analyses (15 min), sample preparation, and a LOD of 1.0 pg mL-1. We glimpse that EEVD meets the principles of robustness and accuracy, desirable analytic parameters for assays destined to pandemics control strategies.
Collapse
Affiliation(s)
- Isabela A Mattioli
- São Carlos Institute of Chemistry, University of São Paulo, São Carlos, SP, 13560-970, Brazil
| | - Karla R Castro
- São Carlos Institute of Chemistry, University of São Paulo, São Carlos, SP, 13560-970, Brazil
| | - Lucyano J A Macedo
- São Carlos Institute of Chemistry, University of São Paulo, São Carlos, SP, 13560-970, Brazil
| | - Graziela C Sedenho
- São Carlos Institute of Chemistry, University of São Paulo, São Carlos, SP, 13560-970, Brazil
| | - Mona N Oliveira
- Biolinker Synthetic Biology EIRELI, São Paulo, 05508-000, Brazil
| | - Iris Todeschini
- Biolinker Synthetic Biology EIRELI, São Paulo, 05508-000, Brazil
| | - Phelipe M Vitale
- Biolinker Synthetic Biology EIRELI, São Paulo, 05508-000, Brazil
| | - Suzete Cleusa Ferreira
- Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Clinical Hospital HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, 01246903, Brazil; Division of Research and Transfusion Medicine, São Paulo Hemocentre Pro-Blood Foundation, São Paulo, 05403000, Brazil
| | - Erika R Manuli
- Institute of Tropical Medicine, Faculty of Medicine, University of São Paulo, 05403-000, Brazil; LIM-46 HC-FMUSP - Laboratory of Medical Investigation, Clinical Hospital, Faculty of Medicine, University of São Paulo, 01246903, Brazil
| | - Geovana M Pereira
- Institute of Tropical Medicine, Faculty of Medicine, University of São Paulo, 05403-000, Brazil
| | - Ester C Sabino
- Institute of Tropical Medicine, Faculty of Medicine, University of São Paulo, 05403-000, Brazil; LIM-46 HC-FMUSP - Laboratory of Medical Investigation, Clinical Hospital, Faculty of Medicine, University of São Paulo, 01246903, Brazil
| | - Frank N Crespilho
- São Carlos Institute of Chemistry, University of São Paulo, São Carlos, SP, 13560-970, Brazil.
| |
Collapse
|